Literature DB >> 19861603

Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors.

Sócrates Herrera1, Olga Fernández, María R Manzano, Bermans Murrain, Juana Vergara, Pedro Blanco, Ricardo Palacios, Juan D Vélez, Judith E Epstein, Mario Chen-Mok, Zarifah H Reed, Myriam Arévalo-Herrera.   

Abstract

Successful establishment of a Plasmodium vivax sporozoite challenge model in humans is described. Eighteen healthy adult, malaria-naïve volunteers were randomly allocated to Groups A-C and exposed to 3 +/- 1, 6 +/- 1, and 9 +/- 1 bites of Anopheles albimanus mosquitoes infected with P. vivax, respectively. Seventeen volunteers developed signs and symptoms consistent with malaria, and geometric mean prepatent periods of 11.1 days (9.3-11) for Group A; 10.8 days (9.8-11.9) for Group B; and 10.6 days (8.7-12.4) for Group C, with no statistically significant difference among groups (Kruskal-Wallis, P = 0.70). One volunteer exposed to eight mosquito bites did not develop a parasitemia. No differences in parasite density were observed and all individuals successfully recovered after anti-malarial treatment. None of the volunteers developed parasite relapses within an 18-month follow-up. In conclusion, malaria-naive volunteers can be safely and reproducibly infected with bites of 2-10 An. albimanus mosquitoes carrying P. vivax sporozoites. This challenge method is suitable for vaccine and anti-malarial drug testing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861603      PMCID: PMC2826834          DOI: 10.4269/ajtmh.2009.09-0194

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

Review 1.  Plasmodium vivax malaria vaccine development.

Authors:  M Arévalo-Herrera; S Herrera
Journal:  Mol Immunol       Date:  2001-12       Impact factor: 4.407

2.  The chemotherapy of rodent malaria XXXVI. Part IV. The activity of a new 8-aminoquinoline, WR 225,448 against exo-erythrocytic schizonts of Plasmodium yoelii yoelii.

Authors:  W Peters; D Ellis; Y Boulard; I Landau
Journal:  Ann Trop Med Parasitol       Date:  1984-10

3.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Authors:  J A Stoute; M Slaoui; D G Heppner; P Momin; K E Kester; P Desmons; B T Wellde; N Garçon; U Krzych; M Marchand
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

4.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

5.  Infectivity of Plasmodium vivax and P. falciparum to Anopheles tessellatus; relationship between oocyst and sporozoite development.

Authors:  A C Gamage-Mendis; J Rajakaruna; S Weerasinghe; C Mendis; R Carter; K N Mendis
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

6.  Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.

Authors:  J D Chulay; I Schneider; T M Cosgriff; S L Hoffman; W R Ballou; I A Quakyi; R Carter; J H Trosper; W T Hockmeyer
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

7.  Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections.

Authors:  G Snounou; S Viriyakosol; W Jarra; S Thaithong; K N Brown
Journal:  Mol Biochem Parasitol       Date:  1993-04       Impact factor: 1.759

8.  Infection with chloroquine-resistant Plasmodium falciparum in man: prepatent periods, incubation periods, and relationships between parasitemia and the onset of fever in nonimmune persons.

Authors:  R D Powell; J V McNamara
Journal:  Ann N Y Acad Sci       Date:  1970-10-30       Impact factor: 5.691

9.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

Authors:  Philip Bejon; John Lusingu; Ally Olotu; Amanda Leach; Marc Lievens; Johan Vekemans; Salum Mshamu; Trudie Lang; Jayne Gould; Marie-Claude Dubois; Marie-Ange Demoitié; Jean-Francois Stallaert; Preeti Vansadia; Terrell Carter; Patricia Njuguna; Ken O Awuondo; Anangisye Malabeja; Omar Abdul; Samwel Gesase; Neema Mturi; Chris J Drakeley; Barbara Savarese; Tonya Villafana; W Ripley Ballou; Joe Cohen; Eleanor M Riley; Martha M Lemnge; Kevin Marsh; Lorenz von Seidlein
Journal:  N Engl J Med       Date:  2008-12-08       Impact factor: 91.245

10.  Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes.

Authors:  M L Salas; J F Romero; Y Solarte; V Olano; M A Herrera; S Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  1994       Impact factor: 2.743

View more
  27 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 2.  Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Authors:  Julie Healer; Alan F Cowman; David C Kaslow; Ashley J Birkett
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 3.  Experimental human challenge infections can accelerate clinical malaria vaccine development.

Authors:  Robert W Sauerwein; Meta Roestenberg; Vasee S Moorthy
Journal:  Nat Rev Immunol       Date:  2011-01       Impact factor: 53.106

4.  Ethical challenges posed by human infection challenge studies in endemic settings.

Authors:  Michael J Selgelid; Euzebiusz Jamrozik
Journal:  Indian J Med Ethics       Date:  2018-09-18

Review 5.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

6.  Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers.

Authors:  James S McCarthy; Paul M Griffin; Silvana Sekuloski; A Taylor Bright; Rebecca Rockett; David Looke; Suzanne Elliott; David Whiley; Theo Sloots; Elizabeth A Winzeler; Katharine R Trenholme
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

7.  Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Authors:  Myriam Arévalo-Herrera; Omaira Vera; Angélica Castellanos; Nora Céspedes; Liliana Soto; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

8.  Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

Authors:  Sócrates Herrera; Yezid Solarte; Alejandro Jordán-Villegas; Juan Fernando Echavarría; Leonardo Rocha; Ricardo Palacios; Oscar Ramírez; Juan D Vélez; Judith E Epstein; Thomas L Richie; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

9.  Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials.

Authors:  Yezid Solarte; María R Manzano; Leonardo Rocha; Hugo Hurtado; Mark A James; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 10.  Malaria modeling: In vitro stem cells vs in vivo models.

Authors:  Florian Noulin
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.